CORRECTION

Correction to: High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells

Z. Zhao¹ · Y. Xu¹ · J. Lu¹ · J. Xue¹ · P. Liu¹

Published online: 20 October 2017

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Correction to: Clin Transl Oncol
DOI 10.1007/s12094-017-1738-7

In the original version of the article, Table 2 was incorrect. The corrected Table 2 is shown here. Therefore, in Results (page 3 of original version, right column, line 13), the OR of non-optimal debulking should read OR = 3.036 with 95% CI 1.452–6.348.

The online version of the original article can be found under doi:[10.1007/s12094-017-1738-7](https://doi.org/10.1007/s12094-017-1738-7).

✉ P. Liu
peishuliu@126.com

¹ Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan 250012, Shandong, People's Republic of China

Table 2 Relationships between the expression of HO-1 protein and clinicopathological characteristics of patients with ovarian cancer

Characteristics	No. Cases	HO-1 expression		<i>P</i> value	OR (95% CI)
		Low	High		
Pathologic type				0.0235	
Serous	117	36	81 (69.2%)	0.6912	
Low-grade serous	58	19	39 (67.2%)		
High-grade serous	59	17	42 (71.2%)		
Mucinous	16	11	5 (31.3%)		
Endometrioid	25	8	17 (68.0%)		
Clear cell carcinoma	21	11	10 (47.6%)		
Others	22	8	14 (63.6%)		
Age				0.4796	
≤ 50	113	44	69 (61.1%)		
> 50	88	30	58 (65.9%)		
Stage				0.0017	3.656 (1.602–8.344)
I–II	154	66	88 (57.1%)		
III–IV	47	8	39 (83.0%)		
Differentiation				0.5572	
G1/G2	112	39	73 (65.2%)		
G3	89	35	54 (60.7%)		
Lymph node metastasis ^a				0.0001	7.779 (2.280–26.540)
No	156	67	89 (57.1%)		
Yes	34	3	31 (91.2%)		
Optimal debulking				0.0029	3.036 (1.452–6.348)
Optimal	146	63	83 (56.8%)		
Non-optimal	55	11	44 (80.0%)		

^aEleven patients without lymph node resection